COREE Company Limited Resubmits HKEX Listing Application, China’s Largest Paediatric Pharmaceutical Marketing & Promotion Service Provider

NewTimeSpace News: Per HKEX disclosures, COREE Company Limited filed its second IPO application for HKEX Main Board listing on 30 June 2026, with CICC appointed as the sole sponsor.

COREE is a diversified healthcare enterprise originating from South Korea with substantial business presence in China. Its core operations cover pharmaceutical marketing, promotion and sales, as well as the R&D, manufacturing and distribution of maternal, infant and nutritional supplements Per Frost & Sullivan industry data based on full-year 2025 revenue:

It is China’s largest service provider specialising in paediatric pharmaceutical marketing, promotion and sales, capturing approximately 17.0% market share in this niche segment;

It ranks top ten in China’s broader pharmaceutical marketing, promotion and sales industry with a 2.0% market share.

The Company’s nationwide sales network spans all 31 provincial-level regions across Chinese mainland. As at 31 December 2025, it partners with over 1,600 distributors, covering roughly 156,000 clinics, 367,000 pharmacies and 1,700 hospitals nationwide.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.